prepared chairside in a closed circuit, for the management of knee osteoarthritis and chronic tendinopathies. Single session. CE-marked.
Request clinical documentation or distributor information for your region.
Knee osteoarthritis and chronic tendinopathies leave clinicians with a narrow therapeutic window: symptomatic medication on one side, surgery on the other. RegenPRP-HA is built for the space in between — an autologous, single-session preparation combining platelet-rich plasma with hyaluronic acid, prepared chairside in a closed circuit.
Knee osteoarthritis is one of the most common causes of chronic pain and reduced mobility in adults, and its prevalence rises steadily with age and activity level. Chronic tendinopathies — at the elbow, shoulder, patellar or Achilles tendon — follow a similar course: degenerative, slow to resolve, and often resistant to first-line care. For many patients the available options sit at two extremes. Analgesics and anti-inflammatories manage symptoms but do not act on the underlying tissue environment, while surgical intervention is generally reserved for advanced or refractory disease. Between these poles lies a large population of patients who remain symptomatic yet are not surgical candidates. This is the therapeutic gap that autologous biologic approaches aim to address — using the patient’s own platelet-derived components to support the local environment at the treatment site, within a single, reproducible clinical procedure that integrates into routine practice.
RegenPRP-HA brings together two components with complementary roles. The platelet-rich plasma fraction concentrates the patient’s own platelets, which release growth factors involved in the local tissue-repair cascade when delivered to the treatment site. Hyaluronic acid, long established in joint applications, contributes to the viscoelastic properties of the environment and acts as a delivery matrix for the platelet concentrate. Preparing the two together, in a fixed and controlled ratio, is central to the technology: rather than mixing components by hand, the closed-circuit device standardizes the preparation so each session is reproducible from one practitioner to the next. The result is a single autologous product, prepared and applied in one visit, designed to minimize manipulation and the associated contamination risk.
A practical strength of the technology is that the entire preparation happens in a single visit, at the point of care. A small volume of the patient’s own blood is drawn directly into the closed-circuit device. A single centrifugation then separates the blood components and combines the platelet concentrate with hyaluronic acid, with no open transfer between tubes and no manual mixing. The resulting autologous PRP-HA preparation is administered at the treatment site during the same session. Because the circuit is closed and single-use, the workflow is designed to standardize each preparation and reduce the handling steps where variability and contamination typically arise. For the practitioner, this means a procedure that fits into a standard consultation — without a dedicated laboratory, specialized cell-processing equipment, or a return visit for the patient. Full preparation and administration protocols are detailed on the product page.
Reproducibility is a recurring theme in the literature on platelet-based preparations, because outcomes are hard to interpret when the product itself varies from one preparation to the next. A closed, standardized system addresses this directly, delivering a consistent platelet and hyaluronic-acid ratio across sessions and across practitioners. RegenLab’s regenerative technologies are documented in a body of independent, peer-reviewed publications spanning orthopedic and musculoskeletal applications, which clinicians can consult when evaluating the approach for their own practice. Rather than reproduce individual study conclusions here, our science hub gathers the references relevant to each indication in one place — so the evidence can be reviewed in context, and against the claims authorized in each market. Practitioners considering RegenPRP-HA are encouraged to review both the published literature and the regulatory documentation applicable to their region before use.
It combines autologous platelet-rich plasma with hyaluronic acid in a single preparation.
Primarily knee osteoarthritis and chronic tendinopathies.
A small blood draw is processed in a single centrifugation within the closed-circuit device, then applied in the same session — no open manipulation.
Yes, under the EU Medical Device Regulation (MDR).
Via the contact form; our team routes you to the right distributor for your region.